DE69904712D1 - Verwendung von deltorphin zur behandlung von zytokin-vermittelter leberschädigung - Google Patents

Verwendung von deltorphin zur behandlung von zytokin-vermittelter leberschädigung

Info

Publication number
DE69904712D1
DE69904712D1 DE69904712T DE69904712T DE69904712D1 DE 69904712 D1 DE69904712 D1 DE 69904712D1 DE 69904712 T DE69904712 T DE 69904712T DE 69904712 T DE69904712 T DE 69904712T DE 69904712 D1 DE69904712 D1 DE 69904712D1
Authority
DE
Germany
Prior art keywords
seq
deltorphin
deltorphine
cytokin
damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69904712T
Other languages
English (en)
Inventor
R Oeltgen
I Mcclain
Shirish Barve
D Bishop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
University of Kentucky Research Foundation
Original Assignee
Zymogenetics Inc
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, University of Kentucky Research Foundation filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DE69904712D1 publication Critical patent/DE69904712D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69904712T 1998-05-01 1999-04-30 Verwendung von deltorphin zur behandlung von zytokin-vermittelter leberschädigung Expired - Lifetime DE69904712D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7125598A 1998-05-01 1998-05-01
PCT/US1999/009457 WO1999056767A2 (en) 1998-05-01 1999-04-30 Method for treating cytokine mediated hepatic injury

Publications (1)

Publication Number Publication Date
DE69904712D1 true DE69904712D1 (de) 2003-02-06

Family

ID=22100214

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69904712T Expired - Lifetime DE69904712D1 (de) 1998-05-01 1999-04-30 Verwendung von deltorphin zur behandlung von zytokin-vermittelter leberschädigung

Country Status (10)

Country Link
EP (1) EP1073452B1 (de)
JP (1) JP2002513767A (de)
AT (1) ATE230273T1 (de)
AU (1) AU751972B2 (de)
BR (1) BR9909988A (de)
CA (1) CA2326065A1 (de)
DE (1) DE69904712D1 (de)
NZ (1) NZ507775A (de)
WO (1) WO1999056767A2 (de)
ZA (1) ZA200005924B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US6875742B2 (en) * 2000-10-10 2005-04-05 Zymogenetics, Inc. Method for treating cytokine mediated hepatic injury
CN1856504B (zh) 2002-02-06 2010-12-29 史戴西思技术有限公司 抗梗塞分子
US8530515B2 (en) 2010-08-09 2013-09-10 William Brusilow Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response

Also Published As

Publication number Publication date
EP1073452A2 (de) 2001-02-07
AU751972B2 (en) 2002-09-05
ZA200005924B (en) 2002-12-23
NZ507775A (en) 2003-04-29
WO1999056767A3 (en) 2000-03-02
ATE230273T1 (de) 2003-01-15
JP2002513767A (ja) 2002-05-14
WO1999056767A2 (en) 1999-11-11
BR9909988A (pt) 2000-12-26
EP1073452B1 (de) 2003-01-02
CA2326065A1 (en) 1999-11-11
AU3874299A (en) 1999-11-23

Similar Documents

Publication Publication Date Title
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
NO985575L (no) FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese
DE69731540D1 (de) Behandlung von diarrhoe
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE205389T1 (de) Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
NZ335531A (en) Composition and methods of producing human cartilage tissue
ATE342067T1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
DE50014532D1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE69210654D1 (de) Verwendung von Tomoxetine zur Behandlung von Funktionsstörungen der niedrigen Harnwege
PL327181A1 (en) Benzofurane carboxyamides and sulphonamides
ATE172117T1 (de) Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE359798T1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69904712D1 (de) Verwendung von deltorphin zur behandlung von zytokin-vermittelter leberschädigung
ATE170076T1 (de) Angiotensin ii-antagonisten zur behandlung von viralen erkrankungen
DE69904010D1 (de) Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
ATE180277T1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
8332 No legal effect for de